Stay Updated
For all press requests, please reach out to [email protected].
News
Forbes: A Patient's Optimistic Call For Bipartisan Drug-Pricing Reform
March 27,2017 David Mitchell With our nation’s fight over the Affordable Care Act in the rear-view mirror, it’s time for Donald Trump and Congress to focus on a genuinely bipartisan issue: drug prices. According to the Kaiser Family Foundation, 8 in 10 Americans want to allow the government to negotiate prices for people on Medicare. […]
News
Kaiser Health News: "As Drug Costs Soar, People Delay Or Skip Cancer Treatments"
March 15,2017 Liz Szabo John Krahne received alarming news from his doctor last December. His brain tumors were stable, but his lung tumors had grown noticeably larger. The doctor recommended a drug called Alecensa, which sells for more than $159,000 a year. Medicare would charge Krahne a $3,200 copay in December, then another $3,200 in […]
News
Health Affairs Blog: "R&D Costs For Pharmaceutical Companies Do Not Explain Elevated US Drug Prices"
Summary from P4AD: New research debunks the claim that drug corporations must charge U.S. patients high prices to fund new drugs. The research from doctors at Memorial Sloan Kettering Cancer Center is clear: Drug corporations could cut U.S. prices significantly and still cover the full cost the companies claim for research for the entire world. […]
News
Morning Consult: “How Patients Will Take on the Rigged System for Drug Pricing"
March 6, 2017 David Mitchell Every Tuesday for the past nine weeks, I’ve sat in an infusion room for four-and-half hours receiving drugs that cost $13,000. It’s going to be every other Tuesday for the next 14 weeks. Total value of the deal — $208,000. I am very grateful for these drugs. I relapsed months […]
News
Blooomberg: “Drug Costs Too High? Fire the Middleman"
March 3, 2017 Neil Weinberg and Robert Langreth A decade ago, Caterpillar Inc. looked at its employee drug plan and sensed that money was evaporating. The bills for pills had increased inexorably, so the company started to rein in its pharmacy benefit manager, or PBM. The managers are middlemen with murky incentives behind their decisions […]
News
New York Times: “More Than 80 Percent of Patient Groups Accept Drug Industry Funds, Study Shows"
March 1, 2017 Katie Thomas The nation’s largest patient advocacy groups are on the front lines of some of the biggest health care debates, from the soaring costs of prescription drugs to whether new medicines are being approved quickly enough. But while their voices carry weight because they represent the interests of sick patients, a […]
News
Wall Street Journal: “Facing Criticism, Drug Makers Keep Lid On Price Increases"
February 26, 2017 Jonathan D. Rockoff and Peter Loftus Facing mounting criticism about prices, drug companies put some limits on their increases this year. Prescription-drug makers traditionally raise list prices in January. This year, they didn’t raise prices for as many drugs as last year and imposed fewer boosts of 10% or greater, according to […]
News
WBUR: “Not Just Nausea And Vomiting: Cancer Docs Now Worry About 'Financial Toxicity'"
February 24, 2017 Richard Knox Just imagine how it would feel: Your doctor diagnoses cancer. She says there’s a good chance you can beat it, or keep it under control for a long time. But you can’t afford the thousands of dollars you’d have to pay for treatment that your health insurer won’t cover. That […]